India, March 18 -- Shares of Sarepta Therapeutics, Inc. (SRPT) tanked over 24% on Tuesday morning after the company shared an update related to Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy. The company reported that a young man died following treatment with Elevidys, having suffered acute liver failure.
SRPT is currently trading at $76.77, down $24.58 or 24.25%, on the Nasdaq. The stock opened at $78.61 and closed Monday at $101.35. In the past 52 weeks, it has traded between $75.90 and $173.25.
Acute liver injury is a known possible side effect of Elevidys and other AAV-mediated gene therapies and is highlighted in the prescribing information.
googletag.cmd.pus...